The STAY study, a significant clinical trial involving 1,300 dogs across the United States, is testing the drug LOY-002, which aims to extend the lifespan and improve the health of senior dogs. Developed by the biotech firm Loyal, LOY-002 has recently passed a crucial regulatory milestone with the FDA's acceptance of its safety data from over 400 dogs. This proactive approach targets metabolic dysfunction, potentially preventing age-related ailments before they occur. The study is particularly promising as dogs age approximately seven times faster than humans, allowing for quicker observation of the drug's effects. If successful, LOY-002 could be available in veterinary clinics by late 2026, benefiting not only the 500 million pet dogs globally but also the 10.2 million dogs in India. The trial is double-blind, ensuring scientifically valid results, and participants have reported increased energy and activity levels in their dogs. This marks a shift in dog healthcare, viewing aging as a manageable condition rather than an inevitable decline.